CTL Frequency After Mitogen or Antigen IVS
| Reactivity . | . | Patient No. 4 . | Patient No. 5 . | Patient No. 6 . | Patient No. 7 . | ||||
|---|---|---|---|---|---|---|---|---|---|
| . | . | CD4 > 400 . | vCP300 . | CD4 > 400 . | vCP300 . | CD4 < 400 . | vCP300 . | CD4 < 400 . | vCP300 . |
| . | . | PHA . | . | PHA . | . | OKT3 . | . | PHA . | . |
| Anti-Vac | CTLp/106 cells | 22 | 8 | 3 | 3 | 3 | 41 | 3 | 53 |
| Frequency | 1:44,475 | 1:126,904 | 1:311,991 | 1:311,991 | 1:312,022 | 1:24,136 | 1:311,991 | 1:18,702 | |
| 95% CI | 28,621-69,111 | 65,639-245,353 | 115,354-843,824 | 115,354-843,824 | 115,360-843,947 | 16,497-35,314 | 115,354-843,824 | 12,926-27,060 | |
| Anti-Env | CTLp/106 cells | 46 | 52 | 37 | 169 | 3 | 120 | 48 | 115 |
| Frequency | 1:21,535 | 1:19,289 | 1:26,843 | 1:5,9293-150 | 1:312,022 | 1:8,3313-150 | 1:20,686 | 1:8,6713-150 | |
| 95% CI | 14,807-31,319 | 13,680-28,743 | 18,217-39,554 | 4,076-8,626 | 115,360-843,947 | 5,729-12,116 | 14,248-30,032 | 5,966-12,602 | |
| Anti-Gag | CTLp/106 cells | 63 | 46 | 48 | 48 | 76 | 80 | 279 | 142 |
| Frequency | 1:15,959 | 1:21,569 | 1:20,685 | 1:20,685 | 1:13,126 | 1:12,455 | 1:3,576 | 1:7,019 | |
| 95% CI | 11,062-23,023 | 14,830-31,372 | 14,248-30,032 | 14,248-30,032 | 9,026-18,940 | 8,627-17,983 | 2,464-5,191 | 4,820-10,220 | |
| Anti-Pol | CTLp/106 cells | 57 | 8 | 3 | 3 | 7 | 162 | 199 | 309 |
| Frequency | 1:17,6223-150 | 1:126,904 | 1:311,991 | 1:311,991 | 1:145,475 | 1:6,1833-150 | 1:5,025 | 1:3,238 | |
| 95% CI | 12,197-25,460 | 65,639-245,353 | 115,354-843,824 | 115,354-843,824 | 72,237-292,965 | 4,248-8,998 | 3,460-7,297 | 2,227-4,708 | |
| Anti-Nef | CTLp/106 cells | 12 | 40 | 27 | 14 | 37 | 37 | 360 | 106 |
| Frequency | 1:80,916 | 1:25,1893-150 | 1:37,345 | 1:73,460 | 1:26,840 | 1:26,840 | 1:2,7763-150 | 1:9,425 | |
| 95% CI | 46,859-139,726 | 17,170-36,952 | 24,568-56,766 | 43,415-124,299 | 18,215-39,549 | 18,215-39,549 | 1,902-4,051 | 6,494-13,768 | |
| Reactivity . | . | Patient No. 4 . | Patient No. 5 . | Patient No. 6 . | Patient No. 7 . | ||||
|---|---|---|---|---|---|---|---|---|---|
| . | . | CD4 > 400 . | vCP300 . | CD4 > 400 . | vCP300 . | CD4 < 400 . | vCP300 . | CD4 < 400 . | vCP300 . |
| . | . | PHA . | . | PHA . | . | OKT3 . | . | PHA . | . |
| Anti-Vac | CTLp/106 cells | 22 | 8 | 3 | 3 | 3 | 41 | 3 | 53 |
| Frequency | 1:44,475 | 1:126,904 | 1:311,991 | 1:311,991 | 1:312,022 | 1:24,136 | 1:311,991 | 1:18,702 | |
| 95% CI | 28,621-69,111 | 65,639-245,353 | 115,354-843,824 | 115,354-843,824 | 115,360-843,947 | 16,497-35,314 | 115,354-843,824 | 12,926-27,060 | |
| Anti-Env | CTLp/106 cells | 46 | 52 | 37 | 169 | 3 | 120 | 48 | 115 |
| Frequency | 1:21,535 | 1:19,289 | 1:26,843 | 1:5,9293-150 | 1:312,022 | 1:8,3313-150 | 1:20,686 | 1:8,6713-150 | |
| 95% CI | 14,807-31,319 | 13,680-28,743 | 18,217-39,554 | 4,076-8,626 | 115,360-843,947 | 5,729-12,116 | 14,248-30,032 | 5,966-12,602 | |
| Anti-Gag | CTLp/106 cells | 63 | 46 | 48 | 48 | 76 | 80 | 279 | 142 |
| Frequency | 1:15,959 | 1:21,569 | 1:20,685 | 1:20,685 | 1:13,126 | 1:12,455 | 1:3,576 | 1:7,019 | |
| 95% CI | 11,062-23,023 | 14,830-31,372 | 14,248-30,032 | 14,248-30,032 | 9,026-18,940 | 8,627-17,983 | 2,464-5,191 | 4,820-10,220 | |
| Anti-Pol | CTLp/106 cells | 57 | 8 | 3 | 3 | 7 | 162 | 199 | 309 |
| Frequency | 1:17,6223-150 | 1:126,904 | 1:311,991 | 1:311,991 | 1:145,475 | 1:6,1833-150 | 1:5,025 | 1:3,238 | |
| 95% CI | 12,197-25,460 | 65,639-245,353 | 115,354-843,824 | 115,354-843,824 | 72,237-292,965 | 4,248-8,998 | 3,460-7,297 | 2,227-4,708 | |
| Anti-Nef | CTLp/106 cells | 12 | 40 | 27 | 14 | 37 | 37 | 360 | 106 |
| Frequency | 1:80,916 | 1:25,1893-150 | 1:37,345 | 1:73,460 | 1:26,840 | 1:26,840 | 1:2,7763-150 | 1:9,425 | |
| 95% CI | 46,859-139,726 | 17,170-36,952 | 24,568-56,766 | 43,415-124,299 | 18,215-39,549 | 18,215-39,549 | 1,902-4,051 | 6,494-13,768 | |
95% Confidence intervals (CI) for PHA and vCP300 do not overlap.